This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Understand the cash flow statement for Replimune Group, Inc. (REPL), learn where the money comes from and how the company spends it.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

Dividend Yield 5 Year Avg. Replimune has a price-to-earnings (P/E) ratio of -2.06 (TTM). This compares to an industry average of -10.55. What is Replimune’s price-to-book (P/B) ratio? Replimune’s ...

Find out the direct holders, institutional holders and mutual fund holders for Replimune Group, Inc. (REPL).